Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose
Authors:
Open Access
- 5 August 2016
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (9) , 2322-2326
Abstract
Objective: Compare immune persistence from one dose of each of 3 different hepatitis A vaccines when given to school-age children: a domestic, live attenuated hepatitis A vaccine (H2 vaccine); a domestic inactivated hepatitis A vaccine (Healive®); and an imported, inactivated hepatitis A vaccine (Havrix®),.Methods: School-age children were randomized into 1 of 4 groups to receive a single dose of a vaccine: H2 vaccine, Healive®, Havrix®, or hepatitis B vaccine [control]. Serum samples were collected 12 and 24 months after vaccination for measurement of anti-HAV IgG using microparticle enzyme immunoassay. Seropositivity was defined as ≥ 20 mUI/ml. We compared groups on seropositivity and geometric mean concentration (GMC). Results: Seropositive rates for the H2, Healive®, Havrix®, and control groups were 64%, 94.4%, 73%, and 1.0%, respectively, 12-months post-vaccination; and 63%, 95.6%, 72%, and 1.0%, respectively 24-months post-vaccination. Seropositivity was greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.001) and 24 months (p-values < 0.0001). Average GMCs for the H2, Healive®, Havrix®, and control groups, in mIU/ml, were 29.7, 81.0, 36.4, and 2.9, respectively at 12 months, and 30.9, 112.2, 44.3, and 2.9, respectively, at 24 months. GMCs were greater for Healive® than for H2 and Havrix® at 12 months (p-values < 0.0001 and < 0.001, respectively) and 24 months (p-values < 0.001). No statistically significant differences in seropositivity or GMC were found within groups between 12 and 24 months. Conclusion: Immunity persisted 24 months after a single dose of inactivated hepatitis A vaccine and live attenuated hepatitis A vaccine.Keywords
This publication has 15 references indexed in Scilit:
- Live attenuated hepatitis A vaccines developed in ChinaHuman Vaccines & Immunotherapeutics, 2013
- Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccinesHuman Vaccines & Immunotherapeutics, 2013
- [Evaluation on the effect of immunization and safety of live attenuated and inactivated hepatitis A vaccine in China].2013
- WHO position paper on hepatitis A vaccines: June 2012—RecommendationsVaccine, 2013
- Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese childrenVaccine, 2012
- [The immunogenicity and impact factors of hepatitis A attenuated live vaccine and inactivated vaccine].2009
- Incidence of Hepatitis A in Argentina after vaccinationJournal of Viral Hepatitis, 2008
- Hepatitis A and B vaccination and public healthJournal of Viral Hepatitis, 2007
- Hepatitis A booster vaccination: is there a need?The Lancet, 2003
- Excellent Booster Response 4-6 y after a Single Primary Dose of an Inactivated Hepatitis A VaccineScandinavian Journal of Infectious Diseases, 2002